Innate Pharma: green light from the FDA for a study

(CercleFinance.com) - Innate Pharma announced today that the U.
S. Food and Drug Administration (FDA) has approved the initiation of clinical development and a Phase 1 clinical trial of its antibody-drug conjugate (ADC) IPH4502, which it plans to begin in the coming months.

The open-label, multi-center study will include a Part 1 dose escalation and a Part 2 dose optimization study. It will evaluate the safety, tolerability and preliminary efficacy of IPH4502 as a single agent in certain advanced solid tumors.

More specifically, ADC will be studied in tumors known to express Nectin-4, such as urothelial carcinoma, non-small cell lung, breast, ovarian, gastric or colorectal cancers.

Copyright (c) 2024 CercleFinance.com. All rights reserved.